South Africa's hopes of winning the second Test at the Wanderers and squaring the three-Test series against India will rest squarely on the shoulders of their captain Dean Elgar who battled for three hours on Wednesday to keep the Indian bowlers at bay.
The 34-year-old opening batsman produced a defiant 46 not out against a hostile Indian attack as South Africa, chasing 240 to win, reached 118 for two at the close of the third day.
On a difficult pitch, which is likely to pose even greater problems on Thursday, Elgar faced 121 balls in a three-hour examination of his skills and resolve.
He was beaten by several deliveries and took blows to the body, neck and fingers, twice needing treatment on the field. But his resolve was an example to his teammates.
“His leadership will go a long way to getting us across the line,” said South African batting consultant Justin Sammons.
“He’s a competitor at heart. That’s what he loves about Test cricket. It brings out the best in him.”
With Aiden Markram and Keegan Petersen already back in the pavilion and Rassie van der Dussen resuming on 11 not out, Sammons admitted that it was still going to be a tough battle for the Proteas to score the remaining 122 runs they need for victory.
“It’s not going to be easy," he said. "Their attack has been pretty relentless throughout the series and we know what the wicket has been like.”
Indian batsman Ajinkya Rahane said it was a pitch on which one wicket could lead to several.
“We have to keep it tight, keep our intent going and wait for that one wicket,” he said.
Teammate Cheteshwar Pujara, who shared a 111-run third wicket partnership with Rahane to ensure that South Africa were set a challenging target, said he expected the pitch to continue to deteriorate on Thursday, adding that India were “very confident” of winning the Test to go 2-0 up in the series.
- 'Big first hour' -
The early exchanges on Thursday are likely to be crucial. Both camps said the use of the heavy roller at the start of an innings and before play each day provided a window of opportunity for batsmen.
Pujara and Rahane added 66 in the first hour on Wednesday before conditions became more difficult, while Elgar and Markram put on 47 for the first wicket at the start of the final innings, scoring at nearly five runs an over.
“With the roller, the pitch flattens out for half an hour, 40 minutes, then it becomes really hard for the batsmen,” said Rahane.
“We’ve got a big first hour to get through,” said Sammons. “Hopefully the heavy roller plays its part as it has done previously.”
Markram stroked 31 off 38 balls before he fell leg before wicket to first innings bowling hero Thakur.
But it was off-spinner Ravichandran Ashwin who made the second breakthrough when he trapped Petersen in front of his stumps for 28 with the total on 93.
After losing the first Test in Centurion, South Africa, with only six recognised batsmen, need to win to keep the series alive ahead of next week’s third and final Test in Cape Town.
India’s second innings total of 266 owed much to Pujara and Rahane, who shared the biggest partnership of the match.
The two veterans, the subject of criticism after a string of low scores, both went to rapid half-centuries as they took advantage of inconsistent bowling by South Africa.
Pujara said neither batsmen had been concerned about the criticism.
“It’s just the outside noise,” he said. “There are times when you don’t get runs but if you follow the right processes you can put runs on the board.”
Fast bowler Kagiso Rabada brought South Africa back into contention with a burst of three wickets, dismissing both set batsmen as well as wicketkeeper Risabh Pant.
Hanuma Vihari made 40 not out and there was aggressive batting from Ashwin and Thakur as India added 99 for the loss of their last five wickets.
UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.
Investment gap
Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.
Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.
Richard Torbett, ABPI Chief Executive, noted “The UK can lead globally in medicines and vaccines, unlocking billions in R&D investment and improving patient access but only if barriers are removed and innovation rewarded.”
The UK invests just 9% of healthcare spending in medicines, compared with 17% in Spain, and only 37% of new medicines are made fully available for their licensed indications, compared to 90% in Germany.
Expert reviews
Shailesh Solanki, executive editor of Pharmacy Business, pointed that “The government’s own review shows the sector is underfunded by about £2 billion per year. To make transformation a reality, this gap must be closed with clear plans for investment in people, premises and technology.”
The National Institute for Health and Care Excellence (NICE) cost-effectiveness threshold £20,000 to £30,000 per Quality-Adjusted Life Year (QALY) — has remained unchanged for over two decades, delaying or deterring new medicine launches. Raising it is viewed as vital to attracting foreign investment, expanding patient access, and maintaining the UK’s global standing in life sciences.
Guy Oliver, General Manager for Bristol Myers Squibb UK and Ireland, noted that " the current VPAG rate is leaving UK patients behind other countries, forcing cuts to NHS partnerships, clinical trials, and workforce despite government growth ambitions".
Reeves’ push for reform, supported by the ABPI’s Competitiveness Framework, underlines Britain’s intent to stay a leading hub for pharmaceutical innovation while ensuring NHS patients will gain faster access to new treatments.
By clicking the 'Subscribe’, you agree to receive our newsletter, marketing communications and industry
partners/sponsors sharing promotional product information via email and print communication from Garavi Gujarat
Publications Ltd and subsidiaries. You have the right to withdraw your consent at any time by clicking the
unsubscribe link in our emails. We will use your email address to personalize our communications and send you
relevant offers. Your data will be stored up to 30 days after unsubscribing.
Contact us at data@amg.biz to see how we manage and store your data.